MONTANER, J.; RAMIRO, L.; SIMATS, A.; TIEDT, S.; MAKRIS, K.; JICKLING, G. C.; DEBETTE, Stephanie; SANCHEZ, J. C.; BUSTAMANTE, A.

doi:10.1038/s41582-020-0350-6

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Nature Reviews Neurology. 2020, vol. 16, n° 5, p. 247-264

Résumé en anglais

Despite many years of research, no biomarkers for stroke are available to use in clinical practice. Progress in high-throughput technologies has provided new opportunities to understand the pathophysiology of this complex disease, and these studies have generated large amounts of data and information at different molecular levels. The integration of these multi-omics data means that thousands of proteins (proteomics), genes (genomics), RNAs (transcriptomics) and metabolites (metabolomics) can be studied simultaneously, revealing interaction networks between the molecular levels. Integrated analysis of multi-omics data will provide useful insight into stroke pathogenesis, identification of therapeutic targets and biomarker discovery. In this Review, we detail current knowledge on the pathology of stroke and the current status of biomarker research in stroke. We summarize how proteomics, metabolomics, transcriptomics and genomics are all contributing to the identification of new candidate biomarkers that could be developed and used in clinical stroke management.< Réduire

Mots clés

VINTAGE

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés

URI

DOI

Unités de recherche